These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17071154)

  • 41. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
    Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Aldosterone antagonists for all patients with heart failure?].
    Bauersachs J
    MMW Fortschr Med; 2009 Apr; 151(15):33-5. PubMed ID: 19728679
    [No Abstract]   [Full Text] [Related]  

  • 43. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift.
    Epstein M
    J Hypertens; 2001 May; 19(5):829-42. PubMed ID: 11393664
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aldosterone receptor antagonists--how cardiovascular actions may explain their beneficial effects in heart failure.
    Ovaert P; Elliott J; Bernay F; Guillot E; Bardon T
    J Vet Pharmacol Ther; 2010 Apr; 33(2):109-17. PubMed ID: 20444035
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Mineralocorticoid receptor antagonists in chronic kidney disease - pros and cons].
    Jędras M; Filipowicz E
    Wiad Lek; 2017; 70(6 pt 2):1205-1208. PubMed ID: 29533915
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of aldosterone blockers in the management of chronic heart failure.
    Coca SG; Perazella MA
    Am J Med Sci; 2005 Oct; 330(4):176-83. PubMed ID: 16234610
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aldosterone in renal disease.
    Ibrahim HN; Hostetter TH
    Curr Opin Nephrol Hypertens; 2003 Mar; 12(2):159-64. PubMed ID: 12589176
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of aldosterone in congestive heart failure.
    Weber KT; Villarreal D
    Postgrad Med; 1993 Apr; 93(5):203-7, 211-2, 216-8 passim. PubMed ID: 8460078
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aldosterone in renal disease.
    Hostetter TH; Rosenberg ME; Ibrahim HN; Juknevicius I
    Curr Opin Nephrol Hypertens; 2001 Jan; 10(1):105-10. PubMed ID: 11195042
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The renal effects of mineralocorticoid receptor antagonists.
    Bianchi S; Batini V; Bigazzi R
    Int J Cardiol; 2015 Dec; 200():20-4. PubMed ID: 26049733
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction.
    Trachtman H; Weiser AC; Valderrama E; Morgado M; Palmer LS
    J Urol; 2004 Oct; 172(4 Pt 2):1590-4. PubMed ID: 15371767
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aldosterone and progression of renal disease.
    Wenzel U
    Curr Opin Nephrol Hypertens; 2008 Jan; 17(1):44-50. PubMed ID: 18090669
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aldosterone blockade in chronic kidney disease: can it improve outcome?
    Toto RD
    Curr Opin Nephrol Hypertens; 2010 Sep; 19(5):444-9. PubMed ID: 20625290
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aldosterone: Essential for Life but Damaging to the Vascular Endothelium.
    Crompton M; Skinner LJ; Satchell SC; Butler MJ
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Outcomes in Dialysis Patients: Prospects for Improvement with Aldosterone Receptor Antagonists.
    Suthar SD; Middleton JP
    Semin Dial; 2016; 29(1):52-61. PubMed ID: 26242304
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aldosterone blockade: the heart versus the kidney.
    Bhandari S
    Kidney Int; 2012 Nov; 82(10):1136; author reply 1136-7. PubMed ID: 23128119
    [No Abstract]   [Full Text] [Related]  

  • 57. [Renal function in heart failure patients. Prognostic influence and therapeutic implications].
    González-Juanatey JR; Grigorián L; Otero Raviña F
    Med Clin (Barc); 2009 May; 132 Suppl 1():13-9. PubMed ID: 19460475
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Renal alterations in chronic respiratory insufficiency physiopathologic considerations (author's transl)].
    Cruz-Hernandez JJ; Diez-Jarilla JL; Pino J; Laso FJ
    Schweiz Rundsch Med Prax; 1981 Jun; 70(27):1228-32. PubMed ID: 7024975
    [No Abstract]   [Full Text] [Related]  

  • 59. Mineralocorticoid receptor blockers for moderate kidney dysfunction: more merit than ever?
    Mukoyama M; Kuwabara T; Adachi M
    Hypertens Res; 2021 Oct; 44(10):1352-1354. PubMed ID: 34267356
    [No Abstract]   [Full Text] [Related]  

  • 60. The discovery, isolation and identification of aldosterone: reflections on emerging regulation and function.
    Tait SA; Tait JF; Coghlan JP
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):1-21. PubMed ID: 15134795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.